Ver el código de «Bivalirudin»

==Administration==
*Type: [[Anticoagulant]] (Direct thrombin inhibitor)
*Dosage Forms: powder for injection
*Dosage Strengths: 250mg
*Routes of Administration: IV
*Common Trade Names: Angiomax, Angiox

==Adult Dosing==
*Acute MI, adjunct to thrombolysis: 0.25 mg/kg IV bolus + 0.5 mg/kg/hr x 12h, then 0.25 mg/kg/hr x 36h
*PCI Thrombosis prophylaxis: 0.75 mg/kg IV bolus + 1.75 mg/kg/hr IV infusion during procedure + 0.2mg/kg/hr x 4-20h after procedure
*Unstable angina/NSTEMI: 0.1 mg/kg IV bolus + 0.25 mg/kg/hour IV infusion

==Pediatric Dosing==
''Safety/efficacy not established''

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B
*[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out
*Renal dosing: no adjustment in bolus dosing
**CrCl 30-59 mL/min: no adjustment in infusion or bolus dose
**CrCl <30: consider reducing infusion to 1 mg/kg/hr
**Hemodialysis: Reduce infusion rate to 0.25 mg/kg/hr
*Hepatic dosing: 

==Contraindications==
*Allergy to class/drug
*Active major bleeding

==Adverse Reactions==
===Serious===
*Major bleeding: retroperitoneal, intracranial hemorrhage
*Coronary artery stent thrombosis, ventricular fibrillation
*Thrombosis
*Cerebral ischemia
*Peripheral facial palsy
*Oliguria, renal failure
*Sepsis
===Common===
*Hypotension
*Minor bleeding
*Nausea
*Headache, backache, pain

==Pharmacology==
*Half-life: 25 min
*Metabolism: Blood proteases
*Excretion: Renal

==Mechanism of Action==
*Binds to and inhibits thrombin

==Comments==


==Indications by Condition==
''The following table is automatically generated from disease/condition pages across WikEM.''

{{#ask:[[Has DrugName::Bivalirudin]]
 |?Has Indication=Indication
 |?Has Dose=Dose
 |?Has Context=Context
 |?Has Route=Route
 |?Has Population=Population
 |format=table
 |headers=plain
 |mainlabel=-
 |sort=Has Indication
 |limit=50
}}

==See Also==
*[[Coagulopathy (main)]]
*[[Anticoagulant reversal for life-threatening bleeds]]

==References==
*Allie DE, Lirtzman MD, Wyatt CH, et al, “Bivalirudin as a Foundation Anticoagulant in Peripheral Vascular Disease: A Safe and Feasible Alternative for Renal and Iliac Interventions," J Invasive Cardiol, 2003, 15(6):334-42. [PubMed 12777673]
*Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. J Am Coll Cardiol. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017. [PubMed 25260718]
*Angiomax (bivalirudin) [prescribing information]. Princeton, NJ: Sandoz Inc; February 2019.
*Angiomax (bivalirudin) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc.; September 2016.
*Antman EM, “Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions?” JAMA, 2003, 289:903-5. [PubMed 12588276]
*Aggarwal A, Sobel BE, and Schneider DJ, “Decreased Platelet Reactivity in Blood Anticoagulated With Bivalirudin or Enoxaparin Compared With Unfractionated Heparin: Implications for Coronary Intervention,” J Thromb Thrombolysis, 2002, 13:161-5. [PubMed 12355033]
*Bittl JA, Chaitman BR, Feit F, et al, “Bivalirudin Versus Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina: Final Report Reanalysis of the Bivalirudin Angioplasty Study,” Am Heart J, 2001, 142:952-9. [PubMed 11717596]
*Bittl JA, Strony J, Brinker JA, et al, “Treatment With Bivalirudin (Hirulog) as Compared With Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina. Hirulog Angioplasty Study Investigators,” N Engl J Med, 1995, 333(12):764-9. [PubMed 7643883]
*Bivalirudin injection [prescribing information]. Deerfield, IL: Baxter Healthcare; May 2018.
*Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489. [PubMed 30482768]

<references/>
[[Category:Pharmacology]]